カテゴリ： GlobalData, アメリカ, 企業調査

BioTime Inc (BTX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：BioTime Inc (BTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3416
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：86
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also developing Renevia facial aesthetics product, a potential treatment for facial lipoatrophy; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccines; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. BioTime’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. Its products are developed on its pluripotent stem technology. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

BioTime Inc (BTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
BioTime Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
AgeX Therapeutics Acquires Patents and Patent Applications from Escape Therapeutics 15
BioTime Completes Acquisition Of Stem Cell Assets From Geron 16
Venture Financing 18
AgeX Therapeutics Raises USD0.5 Million in Venture Financing 18
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 19
Partnerships 20
BioTime and Hepregen Form Joint Venture 20
Licensing Agreements 21
Processa Pharma Enters into Licensing Agreement with BioTime 21
BioTime Enters into Licensing Agreement with Hadassah Medical 22
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 23
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 24
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 26
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 27
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 28
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 29
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 30
Equity Offering 31
BioTime Completes Public Offering of Shares for USD28.8 Million 31
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 33
BioTime to Raise up to USD25 Million in Private Placement of Shares 35
BioTime Raises USD20 Million in Public Offering of Shares 36
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 38
BioTime Raises USD5 Million in Private Placement of Shares 40
BioTime Raises USD20.4 Million in Private Placement of Shares 41
BioTime Raises USD8.6 Million in Private Placement of Shares 43
BioTime Raises USD29 Million in Private Placement of Shares 44
BioTime Completes Private Placement Of Shares For US$6.4 Million 46
BioTime Announces Public Offering Of Shares For Up To US$15 Million 47
BioTime Completes Public Offering Of Shares For US$3.5 Million 48
BioTime Completes Private Placement Of Units For US$9 Million 49
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 50
BioTime Announces Private Placement Of Common Stock 52
Acquisition 53
BioIVT Acquires Ascendance Biotech 53
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 54
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 56
BioTime Inc – Key Competitors 58
BioTime Inc – Key Employees 59
BioTime Inc – Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Joint Venture 61
Recent Developments 62
Strategy And Business Planning 62
Apr 06, 2017: BioTime Forms New Subsidiary AgeX Therapeutics to Develop its Programs Focused on Human Aging 62
Financial Announcements 63
Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 63
May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 65
Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 67
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 69
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 71
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 73
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 75
Corporate Communications 78
Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 78
Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 79
Government and Public Interest 80
Jun 29, 2018: BioTime Awarded Grant from the National Institutes of Health 80
Jun 29, 2018: BioTime Awarded Grant From the NIH (National Institutes of Health) 81
May 02, 2018: AgeX Announces NIH Grant Award 82
Sep 18, 2017: BioTime Awarded Grant from the NIH 83
Product News 84
Jan 02, 2018: AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer 84
Other Significant Developments 85
Jun 19, 2017: Biotime Expands & Advances Ophthalmology Portfolio 85
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86

List of Tables
BioTime Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
AgeX Therapeutics Acquires Patents and Patent Applications from Escape Therapeutics 15
BioTime Completes Acquisition Of Stem Cell Assets From Geron 16
AgeX Therapeutics Raises USD0.5 Million in Venture Financing 18
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 19
BioTime and Hepregen Form Joint Venture 20
Processa Pharma Enters into Licensing Agreement with BioTime 21
BioTime Enters into Licensing Agreement with Hadassah Medical 22
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 23
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 24
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 26
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 27
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 28
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 29
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 30
BioTime Completes Public Offering of Shares for USD28.8 Million 31
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 33
BioTime to Raise up to USD25 Million in Private Placement of Shares 35
BioTime Raises USD20 Million in Public Offering of Shares 36
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 38
BioTime Raises USD5 Million in Private Placement of Shares 40
BioTime Raises USD20.4 Million in Private Placement of Shares 41
BioTime Raises USD8.6 Million in Private Placement of Shares 43
BioTime Raises USD29 Million in Private Placement of Shares 44
BioTime Completes Private Placement Of Shares For US$6.4 Million 46
BioTime Announces Public Offering Of Shares For Up To US$15 Million 47
BioTime Completes Public Offering Of Shares For US$3.5 Million 48
BioTime Completes Private Placement Of Units For US$9 Million 49
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 50
BioTime Announces Private Placement Of Common Stock 52
BioIVT Acquires Ascendance Biotech 53
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 54
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 56
BioTime Inc, Key Competitors 58
BioTime Inc, Key Employees 59
BioTime Inc, Subsidiaries 60
BioTime Inc, Joint Venture 61

List of Figures
BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[BioTime Inc (BTX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Volt Information Sciences Inc (VISI)：企業の財務・戦略的SWOT分析
    Volt Information Sciences Inc (VISI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Jacobs Engineering Group Inc (JEC)-石油・ガス分野：企業M&A・提携分析
    Summary Jacobs Engineering Group Inc. (Jacobs) is a provider of technical professional services. The company offers a diverse range of technical, professional, and construction services to industrial, commercial, and governmental customers across the globe. Its service portfolio includes project; pr …
  • Hyundai Steel Co：戦略・SWOT・企業財務分析
    Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report Summary Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Precision Biosciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Precision Biosciences Inc (Precision BioSciences) is a biotechnology company, which develops and commercializes gene therapy and cancer immunotherapy. The company focuses its ARCUS technology, a proprietary genome editing platform, which combines specificity and efficacy, on the development …
  • Curemark LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary Curemark LLC (Curemark) is a biopharmaceutical company that develops novel therapies for the treatment of neurological disorders. The company’s pipeline products include CM-AT, CM-4612, CM-PK, CM-182, and CM-1212 drug candidates. Its drug candidate CM-AT is a clinical trial for autism, ADHD, …
  • Melkior Resources Inc. (MKR)：企業の財務・戦略的SWOT分析
    Melkior Resources Inc. (MKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Plug Power Inc (PLUG)：企業の財務・戦略的SWOT分析
    Summary Plug Power Inc (Plug Power) is an alternative energy company that designs and develops fuel cell structures. The company’s products comprise gendrive, genkey, material handling products, gensure, genfuel and genfuel for stationary markets products. Its material handling products comprise out …
  • AZTherapies Inc-製薬・医療分野：企業M&A・提携分析
    Summary AZTherapies Inc (AZTherapies) is a clinical-stage drug development company, which focuses on the discovery, development and commercialization of medicines for the treatment of Alzheimer’s disease and other neuroinflammatory and neurodegenerative diseases. Its product pipeline includes the le …
  • Koch Enterprises, Inc.：企業の戦略的SWOT分析
    Koch Enterprises, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • 3D Systems Corp (DDD)：企業の財務・戦略的SWOT分析
    3D Systems Corp (DDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Proserv：石油・ガス：M&Aディール及び事業提携情報
    Summary Proserv is an energy service provider that offers engineering services. The company offers drilling, surface, subsea and decommissioning services. Its subsea services comprise subsea engineering, subsea production equipment and services, subsea components and accessories, subsea production e …
  • Enel Generacion Chile SA：発電所・企業SWOT分析
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • FLSmidth & Co AS (FLS)：企業の財務・戦略的SWOT分析
    FLSmidth & Co AS (FLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Arise AB (ARISE)：企業の財務・戦略的SWOT分析
    Arise AB (ARISE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Apogenix AG：製薬・医療：M&Aディール及び事業提携情報
    Summary Apogenix AG (Apogenix) is a developer of immuno-oncology medicines for the treatment of oncological and malignant hematological diseases. The company’s pipeline drug candidates under clinical development include APG101, a CD95 ligand inhibitor for the treatment of glioblastoma and myelodyspl …
  • ABITEC Corp：企業の戦略的SWOT分析
    ABITEC Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • SGS SA (SGSN)：企業の財務・戦略的SWOT分析
    SGS SA (SGSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Bilfinger SE (GBF)：石油・ガス：M&Aディール及び事業提携情報
    Summary Bilfinger SE (Bilfinger) is a provider of industrial engineering services. It offers a wide range of services from consulting, construction, manufacturing, plant expansion to maintenance and project management services across diverse end markets. The company’s major service offerings include …
  • Sino Gas & Energy Holdings Ltd (SEH)：石油・ガス：M&Aディール及び事業提携情報
    Summary Sino Gas & Energy Holdings Ltd (Sino Gas), a subsidiary of MIE Holdings Corp, is an oil and gas company that explores and develops unconventional gas assets production sharing contracts. The company holds working interest in the Linxing PSC and the Sanjiaobei PSC projects. It has strategic A …
  • Lanxess AG (LXS)：企業の財務・戦略的SWOT分析
    Lanxess AG (LXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆